AESARA - Research

Research

Posters

World EPA Congress 2026

Navigating the Medicare and Medicaid Most Favored Nation (MFN) Pricing Landscape: Implications for U.S. Launch Planning and Access Strategy

EUR contact: Jennifer Cain Birkmose

US contact: Amy Winnen

ISPOR 2026

How Payers Read the Tea Leaves: Economic and Formulary Signals from IRA and MFN

Amy Winnen, Ian Javier, Michael McGinty, Susan Hogue

HPR20

ISPOR 2026

Characterizing the Use of Digital Health Technology–Derived Endpoints to Capture Patient Experience Data in Clinical Trials

Khang Nguyen, Jaymin Patel, Danny Yeh

PCR37

ISPOR 2026

A Descriptive Comparison of U.S. Medicare IRA Negotiated Prices and Average MFN Benchmarks for Part D Drugs

Chad Patel, Neha Pethad, Paige Ngo

HPR2

ISPOR 2026

Budget Impact of Expanding Medicare Coverage for GLP-1 Receptor Agonists in the Treatment of Obesity Under Alternative Pricing Scenarios

Paige Ngo, Amanda Pan

EE110

ISPOR 2026

When Is Real-World Evidence Scientifically Sound? Expert Consensus on SASS for CFL Communication

Susan Hogue, Richard Stanford, Rachel Black, Jiawei Chen, Yamini Misra, Sissi Pham

HPR101

ISPOR 2026

Embedded Qualitative Interviews – Guidance and Practice by Major HTA Bodies

Amy Wu, Jaymin Patel, Danny Yeh

PCR113

ISPOR 2026

Trends in the Use of Real-World Evidence in Press Releases Issued by the Top 15 Pharmaceutical Companies

Khang Nguyen, Christopher Blanchett, Ruslan Horblyuk, Sissi Pham

RWD137

ISPOR 2026

POSTER TOUR

Using AI to characterize how real-world evidence (RWE) is referenced and positioned on US pharmaceutical HCP product websites.

Keller Balsam, Rachel Black, Yamini Misra, Justin Yu

ISPOR 2026

Implementation of Embedded Qualitative Interviews in Clinical Trials: Insights from the Literature

Jaymin Patel, Khang Nguyen, Denise Garner, Danny Yeh

PCR204

ISPOR 2026

Multimorbidity Patterns Among Functionally Dependent Elderly Adults in the United States: A Latent Class Analysis

Jiawei Chen, Richard Stanford, Carrie Blanchard, Joshua Thorpe

EPH134

ISPOR 2026

Cost-Consequence Model Comparing Originator
r-hFSH-alfa to Other r-FSH-alfa Options in up to Three Complete Ovarian Stimulation Cycles in Assisted Reproductive Technology in China

Haining Luo, Kemal Uca, Juan Enrique Schwarze, Claudia Roeder, Roberta Longo, Cristina Masseria, Ani Qin, Weidong Zhang, Ziyang Li, Lin Zhu.

EE492

Posters

ISPOR 2025

Value Communications With US Payers: The Value of Storytelling

Rachel Black, Susan Hogue, Sissi Pham

HPR90

ISPOR 2025

Sizing up the gap: Evaluating sample size justification in prospective real-world studies

Sarah Bandy, Jaymin Patel, Danny Sheinson, Danny Yeh

ISPOR 2025

A Comparative Assessment of ICER-Sponsored Versus Pharma-Sponsored Cost-Effectiveness Analysis

Paige Ngo, Dan Gratie, Richard Stanford, Lorie Mody

ISPOR 2025

Is the IRA Drug Price Negotiation an Evidence-Based Practice? A Critical Analysis of the Evidence Reviewed by CMS for IRA Drug Price Negotiations and Implications for Future Submissions

Dan Gratie, Jiawei Chen, Amy Wu, Sarah Bandy, Cri Masseria, Sissi Pham

HPR75

ISPOR 2025

Revisiting Archetypes: New Archetypes for Strategic Global Value Evidence Planning

Ruchik Patel, Yamini Misra, Yumi Asukai, Denise Globe, Sissi Pham

HTA59

ISPOR 2025

One Size Doesn’t Fit All: Learnings from a Pilot Survey Assessing Preferences for Improvement vs Worsening of Healthcare Professionals

Denise Garner, Jaymin Patel, Danny Yeh

PCR113

ISPOR 2025

Are Workforce Productivity Measures Useful for Formulary Management Decision-Making?

Susan Hogue, David Tabano, Ruchik Patel, Stacey Kowal, Kate Rosettie, Sissi Pham, Bruce W. Sherman

EE129

ISPOR 2025

Expediting Evidence Synthesis: A Review of Recent Research Evaluating Artificial Intelligence's Performance in Evidence Synthesis and Summarization of Clinical Literature

Fadi Manuel, Rachel Black, Tyler Reinsch, Jiawei Chen, Danny Yeh

SA20

ISPOR 2025

The Role of Productivity Measures in Economic Evaluations of Migraine Therapies

A Hudzik, Denise Garner, Er Chen, Chad Patel, Thomas Butt, Danny Yeh

ISPOR 2025

The Role of Productivity Measures in Economic Evaluations of Migraine Therapies

Amy Wu, Paige Ngo, Dan Gratie, Richard Stanford, Lorie Mody

ISPOR 2025

Moving the Needle: Value and Use of Real-World Evidence in Oncology Clinical Pathways Decision-Making

Phoenix Riley, Caitlyn Solem, Sumati Rao, Susan Hogue

HPR24

ISPOR 2025

Health and Economic Value of Pneumococcal Conjugate Vaccine Against Microbial Resistance in Brazil: An Agent-based Simulation Study

Paige Ngo, Amy Wu, Ashley Lee, Sachiko Ozawa

ISPOR 2025

The Unseen Progress: How PROs May Overlook the Value of Slowing Degenerative Decline

Jaymin Patel, Denise Garner, Danny Yeh

Papers

Burden of hypereosinophilic syndromes in the United States: Patients’ perspective

Jared Silver, MD, Anna Kovalszki, Mary Jo Strobel, Dan Gratie, Amy G. Edgecomb, Cara Schmitt, Waseem Ahmed, Arijita Deb

PharmExec

HEOR: From Proving Product Value to Proving Its Own Worth

Yamini Misra, Denise Garner, Sarah Bandy, Sissi Pham

AESARA HEOR Benchmarking Report: 2024

Budget impact analysis (BIA) of the TearCare System for the treatment of meibomian gland dysfunction (MGD)-associated dry eye disease (DED) in the United States (US)

Thomas Chester, Roberta Longo, Cristina Masseria, Phoenix Riley, Chad Patel & Lorie Mody

Posters

ISPOR EU 2024

Is Artificial Intelligence Ready to Tackle Language Barriers for Health Economics and Outcomes Research?

Yeh D, Roeder C, Longo R, Chamoux C, Manuel F, Saito K

MSR55

ISPOR EU 2024

Is The New EU HTA Process Fit For Rare Patient Engagement?

Bahar Nasim, Chamoux Catherine, Outteridge Gavin

HTA304

ISPOR EU 2024

Assessing Health Technology Assessment (HTA) Outcomes for Conditionally Approved Drugs by the European Medicines Agency (EMA) in Germany, France, and England

Gyuenet Alexandra, Chamoux Catherine

HTA83

ISPOR EU 2024

Early Access Programs (EAPs) in France, Reasons for Refusal

Chamoux Catherine, Outteridge Gavin

HTA11

AMCP Foundation 2024 Best Resident/Fellow Poster Award, AMCP Nexus 2024

The Economic Burden of COVID-19 Vaccine Hesitancy: A Systematic Literature Review

Amy Wu, Paige Q. Ngo, Colleen R. Higgins, Sachiko Ozawa

AMCP Nexus 2024

Forecasting the Impact of the Inflation Reduction Act on Pharmaceutical Innovation

Daniel Gratie, Sarah Bandy, Nathan Stokes, William Chen, Tony Pistilli, Greg Warren, Cristina Masseria

Platinum Abstract/Podium Presentation, AMCP Nexus 2024

Does the Maximum Fair Price Accurately Represent the Value of Multi-Indication Products?

Daniel Gratie, PharmD, MS; Ami R. Buikema, MPH; Sarah Bandy, PharmD, PhD; Elizabeth Brooks; Erin Hulbert, MS, MBA; Kristin J. Moore, PhD, MPH, Cristina Masseria, PhD, MSc

Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19-Related Hospitalization and Mortality: A Systematic Literature Review

Cha-Silva A, Gavaghan M, Bergroth T, Nguyen J, Alexander-Parrish R, Yang J, Draica F, Patel J, Garner D, Stanford R, Meier G, McLaughlin JM,

516

ISPOR 2024

The Meteoric Rise of RWE and HEOR: Operating with Efficiency and Fostering Innovation between the Two Groups

Tutino C., Misra Y., Watkins S., de Boer M., Jarrett J

OP10

ISPOR 2024

Development and Validation of a Markov Model for the Evaluation of a One-time Universal Screening for Hepatitis B in Adults

Pan A., Stanford R., Gratie D., Mody L., Reinsch T.

ISPOR 2024

Identification and Characterization of Real-World Evidence Presented on Brand Websites for the Top 20 Medicines with the Highest CMS Expenditure

Jayakumar A., Gratie D., Mody L., Stanford R.

ISPOR 2024

Identifying Gaps in Patient Experience Data for Progressive Supranuclear Palsy

Garner D., Gratie D., Mody L., Stanford R.

Papers

Hereditary factor X deficiency in America survey: impact on quality of life and burden of disease in patients and caregivers

Brian Branchford, Kim Clark, Richard H Stanford, Denise A Garner, Shirley P Huang, Eric Wolford

Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19-Related Hospitalization and Mortality: A Systematic Literature Review

Ashley S Cha-Silva, Meghan B Gavaghan, Tobias Bergroth, Ronika Alexander-Parrish, Jingyan Yang, Florin Draica, Jaymin Patel, Denise A Garner, Richard H Stanford, Genevieve Meier, John M McLaughlin, Jennifer L Nguyen

TearCare system versus cyclosporine ophthalmic emulsion for the treatment of moderate-to-severe meibomian gland disease associated dry eye disease in the United States: a cost-utility analysis

Nathan Lighthizer, Bonnie-Kim Schwertz, Thomas Chester, Roberta Longo, Phoenix Riley, Lorie Mody, Chad Patel

Posters

ISPOR 2023

The Wave of the Future? Alternative Digital Value Communication Solutions to Enhance Engagements between US Payers and MSLs

Reinsch T.K., Mader G., Manuel F., Patel C., Hogue S.

EE218

ISPOR 2023

Patient-Centric Care (PCC) in Higher-Risk Myelodysplastic Syndromes (HR-MDS): A Global Systematic Literature Review (SLR) and Gap Analysis

Armstrong E.P., Franic D., Malone D.C., Pham S.V., Hogea C.

PCR123

AMCP NEXUS 2023

Exploring awareness and perceptions of genetic testing for cancer risks

Garner D., Roberts M.

AMCP NEXUS 2023

Factors associated with recurrent Clostridioides difficile among commercial and Medicare Advantage-insured patients

Barnes T., Gratie D., Stanford R., Buikema A., Le L., Gerdes R., Taneja H., Solow B.

AMCP NEXUS 2023

Abortion medications online in the post-Roe v. Wade era

Higgins C., Lee Y., Jayakumar A., Garner D., Lie G., Ozawa S.

ISPOR Europe 2023

The Price Is Right or Is It? Navigating the Inflation Reduction Act (IRA) With Payer Perspectives on Evidence Needs, Fair Market Pricing, and Patient Access Implications

Chad Patel & Cristina Masseria

HPR83

ISPOR Europe 2023

Exploring the Pandemic's Impact: An Examination of Adolescent and Adult Vaccination Rates in Different Countries During COVID-19

Masseria C., Guyenet A., Mody L., Roeder C., Schliep V.

EPH45

ISPOR Europe 2023

Guideline for Costing in Italian Economic Evaluations: A Proposal of the ISPOR Italy Rome Chapter

Berto P., Jommi C., Marcellusi A., Aiello A., Bianco M., Bini C., Bozzari I., d'Avella M.C., Di Brino E., Moreno C., Mucherino S., Ragonese A., Romano F., Sansone C., Simonelli C., Zucconi A., Canonico P.L.

HTA202

ISPOR Europe 2023

Predicting PICOs for EU Joint Clinical Assessment: Lessons from PICOs in Relative Effectiveness Assessments (REA) from EUnetHTA Joint Action 3 Project

Chamoux C., Outteridge G., Berto P.

ISPOR Europe 2023

Potential Discrepancies/Misalignments in Future EU-HTA Appraisals the POLIVY and Stelara JA3 PICO Example

Berto P., Chamoux C., Outteridge G., Roeder C.

HTA254

ISPOR Europe 2023

Unraveling the Relationship between Expedited Regulatory Approval By the European Medicines Agency (EMA) and Reimbursement Outcomes for Drugs Approved

Guyenet A., Berto P., Chamoux C., Crathorne L., Outteridge G., Roeder C.

HTA251

ISPOR Europe 2023

Does Including Biosimilars Earlier in the Treatment Pathways Lead to Cost Savings in Rheumatology?

Tak S., Methuku M.

HPR192

ISPOR Europe 2023

Economic Burden of Patients in the United States with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Focused Literature Review

Mayen Herrera E., Stanford R., Njue A., Lyall M., Nuabor W., D'Souza V., Dubucq H., Moola S.

ISPOR Europe 2023

Clinical Burden of Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Focused Literature Review

Mayen Herrera E., Stanford R., Njue A., Lyall M., Nuabor W., D'Souza V., Dubucq H., Moola S.

ISPOR 2023

Comprehensive Code List Associated with CDC-Defined High-Risk Underlying Medical Conditions Leading to Potential Progression to Severe COVID-19 Outcomes

Scott A., Draica F., Atkinson J., Chambers R., Reimbaeva M., Stanford R., Edgecomb A., Manuel F.

RWD70

IDWeek 2023

A Systematic Literature Review Evaluating Real-World Use of Nirmatrelvir-Ritonavir for the Prevention of COVID-19-Related Hospitalization and Death

Cha-Silva A, Gavaghan M, Nguyen J, Alexander-Parrish R, Yang J, Patel J, Garner D, Stanford R, Meier G

516

HTRS 2023 Scientific Symposium

Burden of disease and impact on quality of life in hereditary factor X deficiency patients who have experienced menorrhagia: findings from the Hereditary Factor X Deficiency in America survey

Stanford R.H., Clark K., Huang S.P., Branchford B.R.

HTRS 2023 Scientific Symposium

Burden of disease and impact on quality of life in hereditary factor X deficiency patients receiving prophylaxis: findings from the Hereditary Factor X Deficiency in America survey

Garner D.A., Clark K., Huang S.P., Stanford R.H., Branchford B.R.

Papers

The Zero-Price Conundrum: Exploration of Scenarios Where a Clinically Effective New Drug Might Not Be Cost-Effective at Zero Price

Mladsi D., Barnett C.L., Mader G., Russell-Smith T.A., Unuigbe A., Bell T.

RDS-NExT workshop: consensus statements for the use of surfactant in preterm neonates with RDS

Bhandari V., Black R., Gandhi B., Hogue S., Kakkilaya V., Mikhael M., Moya F., Pezzano C., Read P., Roberts K.D., Ryan R.M., Stanford R.H., Wright C.J.

Interpersonal communication-, education- and counselling-based interventions to support adherence to oral anticancer therapy: a systematic review

Elston Lafata J., Nguyen B., Staresinic C., Johnson M., Gratie D., Muluneh B.

Patient Experiences with Clostridioides difficile Infection and Its Treatment: A Systematic Literature Review

Armstrong E.P., Malone D.C., Franic D.M., Pham S.V., Gratie D., Amin A.

The budget impact of introducing the OMNI® surgical system to a United States health plan for managing mild-to-moderate primary open-angle glaucoma

Mader G., Ghinelli F., Torelli F., Patel C., Masseria C., Dickerson J., Nguyen D., Cantor L.

OMNI® surgical system versus iStent inject® with concomitant cataract surgery for the treatment of mild-to-moderate primary open-angle glaucoma in the United States: a cost utility analysis

Longo R., Ghinelli F., Torelli F., Mader G., Masseria C., Patel C., Franic D.M., Dickerson J., Nguyen D., Cantor L.

Validation of a Health-Related Quality of Life Questionnaire in Patients with Recurrent Clostridioides difficile Infection in ECOSPOR III, a Phase 3 Randomized Trial

Lapin B., Garey K.W., Wu H., Pham S.V., Huang S.P., Reese P.R., Wang E., Deshpande A.

Real-world Effectiveness of Dupilumab in Biologic Naïve Patients With Asthma: Analysis From the US Advantage Study

Stanford R.H., Blaiss M., Bleecker E.R., Jacob-Nara J.A., Duh M., Wang Z., Soler X., Hardin M.E., Ye M., Nair R.

Posters

THSNA 2022

Hereditary factor X deficiency burden of disease and impact on quality of life in patients and caregivers: interim findings from the hereditary

Clark K., Huang S.P., Stanford R.H., Branchford B.

AMCP NEXUS 2022

Patient burden of recurrent clostridioides difficile: Recurrence rates and healthcare resource utilization among commercial- and Medicare Advantage-insured populations

Gratie D., Barnes T., Steffens A., Stanford R., Le L., Kirwan B., Black R., Gerdes R., Buikema A.

ISPOR 2022

Leveraging Social Media for Patient Experience Insights in Rare Disease

Black R., Freifeld C., Hogue S., Decoteau S., Pham S.

PCR102

ISPOR 2022

The Evolving Role of Disease-Level Patient Experience in Health Technology Assessment (HTA) and Regulatory Decision-Making

Hudzik A., Sandman K., Pham S.

PCR6

ISPOR Europe 2022

A Targeted Literature Review Into Incorporating Environmental Impact of Healthcare Into Health Technology Assessments (HTAS)

Kiritharakopalan D., Lister J., Outteridge G.J., Patel C., Ozer Stillman I.

HTA117

ISPOR 2022

Cost and Health Care Resource Utilization (HCRU) in Patients Starting Intravitreal Dexamethasone (DEX) or ANTI-Vascular Endothelial Growth Factor (AVEGF) in Patients with Diabetic Macular Edema (DME)

Stanford R., Mercer D.W., Rava A., Crowley A., Zhao C.

EE385

ISPOR 2022

Considerations for New Product Planning in Light of FDA Draft Guidance on Benefit-Risk Assessment

Sandman K., Hudzik A., Pham S.

ISPOR Europe 2022

Price Erosion for Haemato-Oncology Drugs in European Markets

Black R.M., Chamoux C., Outteridge G.J., Tak S.

HPR33

ISPOR 2022

Validation of a Health-Related Quality of Life Questionnaire in Patients with Recurrent Clostridioides Difficile Infection in Ecospor-III, a Phase 3 Randomized Trial

Lapin B., Garey K., Wu H., Pham S., Huang S., Reese P.R., Wang E., McGovern B., Deshpande A.

PCR150

ISPOR 2022

A Systematic Review of Healthcare Resource Use and Costs of the Treatment of Clostridioides Difficile Infections

Malone D.C., Armstrong E., Pham S., Gratie D., Amin A.

EE429

ISPOR Europe 2022

Cost-Effectiveness of OMNI® Surgical System Versus iStent Inject® for the Treatment of Primary Open-Angle Glaucoma in the United States

Longo R., Ghinelli F., Morris L., Liu J., Dickerson J., Patel C., Mader G., Nguyen D., Cantor L.B.

EE401

AMCP 2022

Assessing the cost-effectiveness of various treatments for clostridioides difficile infections: a systematic literature review

Armstrong E., Malone D., Pham S., Gratie D., Amin A.

Posters

AMCP NEXUS 2020

Healthcare economic information and patient experience information in immuno-oncology: Is the research being conducted and communicated effectively to U.S. payers?

Brogan A., Patel C., Schoenherr N., Bobiak S.

ISPOR Europe 2020

Patient Experience Information (PEI) and Patient Involvement in Health Technology Assessment (HTA) Processes in 7 European Countries Using Immuno-Oncology

Brogan A., Patel C.K., Schoenherr N., Bobiak S.

PCN318

ISPOR 2020

Value Communications with US Payers: Can Digital Solutions Help Elevate Patient Access?

Hogue S.L., Zhu L., Reinsch T.K., Gratie D., Brogan A.P., Patel C.K., Wu K.W.K.

PNS131

ISPOR 2019

Unmet Needs Exist In Payer Communications - Are Digital Solutions The Answer?

Hogue S., Brogan A.P., Patel C.

PNS180

ISPOR 2019

Emerging Trends in US HTA: A Systematic Review of ICER Value Assessments to Identify Factors Associated with Recommendations

Kruzikas D.T., Malone D.C., Pham S., Reinsch T.K., Akehurst R.

PMU75

Papers

HTA and economics in the United States: A systematic review of ICER reports to evaluate trends, identify factors associated with recommendations, and understand implications

Kruzikas D.T., Malone D.C., Pham S., Reinsch T.K., Akehurst R.

The Identification and Cost of Acute Chronic Obstructive Pulmonary Disease Exacerbations in a United States Population Healthcare Claims Database

Stanford R.H., Engel-Nitz N.M., Bancroft T., Essoi B.

Validation and assessment of the COPD treatment ratio as a predictor of severe exacerbations

Stanford R.H., Korrer S., Brekke L., Reinsch T., Bengtson L.G.S.

Cost analysis of COPD exacerbations and cardiovascular events in summit

Stanford R.H., Coutinho A.D., Eaddy M., Yue B., Bogart M.

Understanding payer perspectives on value in the use of pharmaceuticals in the United States

Brogan A.P., Hogue S.L., Vekaria R.M., Reynolds I., Coukell A.